Drug intelligence / Profile preview

HAT-06

Development stage: Preclinical
Lead developer: DRC
Modality: Small Molecules
Administration: Inhalation

Overview

HAT-06 is an inhaled pharmaceutical candidate currently in the basic research stage for the treatment of asthma and allergic conditions. It is being developed in-house by **DRC** (Drug Research Center Co., Ltd.), a Japanese company specializing in inhalation drug delivery technologies. While the specific molecular target and mechanism of action have not been publicly disclosed, the drug is designed for local delivery to the respiratory tract to manage symptoms associated with asthma and allergies. As of 2024, the program remains in the early preclinical phase of development in Japan.

Beyond the preview

Go deeper on HAT-06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAT-06.

Explore the full profile